Smith & Nephew (SNN) Stock Analysis – A Brief Overview

By Ken Smith • Saturday, December 28 10:12 • Permanent Link

Join us for a quick overview of Smith & Nephew, a Specialty Industrial Machinery company whose shares moved 1.3% today. Here are some facts about the stock that should help you see the bigger picture:

Smith & Nephew has moved -7.7% over the last year, and the S&P 500 logged a change of 25.9%
Its trailing earnings per share (EPS) is $0.7
Smith & Nephew has a trailing 12 month Price to Earnings (P/E) ratio of 35.4 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $1.29 and its forward P/E ratio is 19.2
The company has a Price to Book (P/B) ratio of 4.16 in contrast to the S&P 500's average ratio of 4.74
Smith & Nephew is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
SNN has reported YOY quarterly earnings growth of 24.4% and gross profit margins of 0.7%
The company has a free cash flow of $247.88 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.